Aldeyra Therapeutics stock up 13% premarket

1 BUSINESS

Business News - Opportunities - Reviews

 

 

Aldeyra Therapeutics announces positive early results in trial of dry eye disease treatment

Aldeyra Therapeutics Inc. shares rose more than 13% in premarket trade Tuesday before surrendering their gains, after the biotech reported positive results in the first part of a late-stage trial of a treatment for dry eye disease. The Lexington, Mass.-based company said the Phase 3 Renew trial of topical ocular reproxalap in patients with dry eye disease involved 422 patients in the first part of the trial. “To our knowledge, reproxalap is the first topical dry eye disease drug to demonstrate statistically significant ocular dryness symptom improvement relative to vehicle as soon as one week after initiation of treatment, and thus has the potential to be first-line therapy,” Chief Executive Todd C. Brady said in a statement. The primary endpoint of the first part of the trial was to confirm dosing, endpoints and sample size for Renew part 2. Dry eye disease is a common disorder affecting about 34 million Americans, and symptoms include dryness, inflammation, pain, discomfort, irritation, diminished quality of life and in severe cases, permanent vision impairment. Aldeyra shares have fallen 10% in 2019, while the S&P 500 has gained 25%.

1 BUSINESS

Business News - Opportunities - Reviews

 

 

Leave a Reply